Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8597)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Dec 27, 2015 (publication date) through Feb 4, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Surgery
ISSN
1948-9366
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Zaniboni A. New active drugs for the treatment of advanced colorectal cancer. World J Gastrointest Surg 2015; 7(12): 356-359 [PMID: 26730280 DOI: 10.4240/wjgs.v7.i12.356] |
|---|---|
| URL: | https://www.wjgnet.com/1948-9366/full/v7/i12/356.htm |
| Number | Citing Articles |
| 1 |
Arthur C. Houts, Sarika Ogale, Nicolas Sommer, Sacha Satram-Hoang, Mark S. Walker. Treatment Patterns and Outcomes in Patients with KRAS Wild-Type Metastatic Colorectal Cancer Treated in First Line with Bevacizumab- or Cetuximab-Containing Regimens. Journal of Gastrointestinal Cancer 2019; 50(1): 69 doi: 10.1007/s12029-017-0027-6
|
| 2 |
Yohei Nose, Yoshinori Kagawa, Taishi Hata, Ryota Mori, Kenji Kawai, Atsushi Naito, Takuya Sakamoto, Kohei Murakami, Yoshiteru Katsura, Yoshiaki Ohmura, Toru Masuzawa, Atsushi Takeno, Yutaka Takeda, Takeshi Kato, Kohei Murata. Neutropenia is an indicator of outcomes in metastatic colorectal cancer patients treated with FTD/TPI plus bevacizumab: a retrospective study. Cancer Chemotherapy and Pharmacology 2020; 86(3): 427 doi: 10.1007/s00280-020-04129-6
|
| 3 |
Antonio Rossi, Tiziana Pia Latiano, Paola Parente, Cinzia Chiarazzo, Filomena Limosani, Gabriele Di Maggio, Evaristo Maiello. The potential role of nintedanib in treating colorectal cancer. Expert Opinion on Pharmacotherapy 2017; 18(11): 1153 doi: 10.1080/14656566.2017.1346086
|
| 4 |
Manuela Porru, Pasquale Zizza, Marco Franceschin, Carlo Leonetti, Annamaria Biroccio. EMICORON: A multi-targeting G4 ligand with a promising preclinical profile. Biochimica et Biophysica Acta (BBA) - General Subjects 2017; 1861(5): 1362 doi: 10.1016/j.bbagen.2016.11.010
|
| 5 |
Arthur C. Houts, Sarika Ogale, Yousuf Zafar, Joleen M. Hubbard, Sacha Satram-Hoang, Nicolas Sommer, Mark S. Walker. Progression-Free Survival in Patients Receiving Chemotherapy Alone (C) or Chemotherapy with Bevacizumab (CB) for First-Line Treatment of KRAS Mutant Metastatic Colorectal Cancer in Community Oncology Settings. Journal of Gastrointestinal Cancer 2019; 50(1): 16 doi: 10.1007/s12029-017-0017-8
|
| 6 |
Jianming Xu, Tae Won Kim, Lin Shen, Virote Sriuranpong, Hongming Pan, Ruihua Xu, Weijian Guo, Sae-Won Han, Tianshu Liu, Young Suk Park, Chunmei Shi, Yuxian Bai, Feng Bi, Joong Bae Ahn, Shukui Qin, Qi Li, Changping Wu, Dong Ma, Donghu Lin, Jin Li. Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study. Journal of Clinical Oncology 2018; 36(4): 350 doi: 10.1200/JCO.2017.74.3245
|
| 7 |
Gianluca Mauri, Viviana Gori, Erica Bonazzina, Alessio Amatu, Federica Tosi, Katia Bencardino, Lorenzo Ruggieri, Giorgio Patelli, Sabrina Arena, Alberto Bardelli, Salvatore Siena, Andrea Sartore-Bianchi. Oxaliplatin retreatment in metastatic colorectal cancer: Systematic review and future research opportunities. Cancer Treatment Reviews 2020; 91: 102112 doi: 10.1016/j.ctrv.2020.102112
|